Jazz Pharmaceuticals plc (JAZZ:NASDAQ) closed at $214.00 on October 23, 2026, down 0.30% on the day. The stock trades 19.7% below its 52-week high of $266.38 and 66.1% above its 52-week low of $128.80. Over the past year, it gained 54.5%. Jazz Pharmaceuticals plc is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, JAZZ closed higher on 133 days (53%). Its best day was November 17, 2025 (+20.57%) and its worst was January 8, 2026 (-5.38%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 2 times.
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evalu...
Find more stocks like JAZZ with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.